Metabolic Dysfunction Associated Steatotic Liver Disease: Making Sense of a New Name, New Guidelines, and New Medication
Featured
Metabolic Dysfunction Associated Steatotic Liver Disease: Making Sense of a New Name, New Guidelines, and New MedicationDr. Maya Balakrishnan discusses the updated guidelines and medical treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), occurring between 2021 and 2024. She emphasizes how these changes affect best practices for clinicians.
CME credit available